Background: Triple-negative breast cancer (TNBC) remains a formidable clinical challenge due to the scarcity of targeted therapies and profound metabolic heterogeneity. Although Artemisian B, a dimeric sesquiterpene lactone derived from Artemisia argyi, exhibits potent antiproliferative activity, its comprehensive metabolic footprint and the translation of these perturbations into downstream signaling regulation remain poorly characterized. Methods: To address this gap, we employed an integrative analytical framework combining untargeted metabolomics, topology-guided metabolite–gene network mapping, and parallel experimental validation in MDA-MB-231 cells. This workflow systematically profiled cellular phenotypes, global metabolic reprogramming, and key signaling nodes, enabling the prioritization of high-confidence mechanistic links between metabolic alterations and signal transduction. Results: Artemisian B dose-dependently suppressed TNBC cell viability (IC50 = 12.12 μM) and triggered mitochondrial apoptosis, characterized by Bax upregulation, Bcl-2 downregulation, and caspase-9/3 activation. Untargeted metabolomics identified 129 significantly altered metabolites, reflecting extensive dysregulation across lipid peroxidation, bioenergetics, and nucleotide metabolism. Topological analysis of the metabolite–gene network identified the NF-κB pathway as a highly interconnected hub within this perturbed landscape. Parallel experimental validation corroborated this prediction, demonstrating that Artemisian B consistently suppressed the phosphorylation of IKKα/β, IκBα, and p65, while markedly attenuating p65 nuclear translocation. Conclusions: Artemisian B induces TNBC apoptosis through extensive metabolic reprogramming coupled with concurrent inhibition of NF-κB signaling. By seamlessly integrating untargeted metabolomics with network topology, our framework not only successfully bridges metabolic perturbations with signaling outcomes but also establishes a versatile, dual-perspective strategy applicable to both biochemical reaction networks and signal transduction pathways. This approach provides a robust predictive paradigm for decoding the multi-target pharmacological mechanisms of natural products.
Given the increasing hepatotoxicity risk associated with pyrrolizidine alkaloids (PAs) in Emilia sonchifolia (L.) DC., this study aimed to systematically characterize its PA components and identify the material basis responsible for liver injury. Using solid-phase extraction (SPE) enrichment coupled with ultra-high-performance liquid chromatography–quadrupole/orbitrap high-resolution mass spectrometry (UHPLC-HRMS), efficient annotation of PAs was achieved through building-block-based molecular network (BBMN) cluster analysis. A total of 76 PAs were identified (66 otonecine-type and 10 retronecine-type PAs), including 35 known compounds (e.g., senkirkine and petasitenine) and 41 potentially novel compounds. Semi-quantitative analysis revealed that senkirkine accounted for 86% of the total PAs. As an otonecine-type diester alkaloid, it serves as the core toxic substance triggering hepatic sinusoidal obstruction syndrome (HSOS). Network toxicology analysis identified 52 intersecting targets between senkirkine and hepatotoxicity. A protein–protein interaction (PPI) network was constructed, revealing 44 connected nodes with MAPK1, AKT1, and PIK3CA as key hub targets. Enrichment analysis indicated that these targets are primarily involved in the PI3K-Akt signaling pathway and focal adhesion. Molecular docking further validated that senkirkine exhibits strong binding affinities with these core targets, with binding energies ranging from −26.33 to −51.50 kcal/mol, stabilized by robust hydrogen-bonding networks. Consequently, senkirkine was identified as the critical safety indicator for quality control, and processing techniques were applied to reduce its content, balancing efficacy and toxicity risks.